Rein Therapeutics (RNTX) Accumulated Depreciation (2016 - 2023)
Rein Therapeutics (RNTX) posted quarterly Accumulated Depreciation of $358000.0 for Q4 2023, up 32.59% year-over-year from $270000.0 in Q4 2022, and up 21.36% quarter-over-quarter from $295000.0 in Q3 2023.
Rein Therapeutics (RNTX) Accumulated Depreciation (2016 - 2023) Analysis & Trends
Rein Therapeutics (RNTX) has reported Accumulated Depreciation for 8 consecutive years, with $358000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Accumulated Depreciation rose 32.59% year-over-year to $358000.0; the TTM figure through Dec 2023 stood at $358000.0 (up 32.59% YoY), while the FY2023 annual figure was $358000.0, up 32.59% from the prior year.
- Accumulated Depreciation climbed to $358000.0 in Q4 2023 per RNTX's latest filing, from $295000.0 in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $629000.0 in Q3 2020 and bottomed at $166000.0 in Q4 2020.
- Historically, Accumulated Depreciation has averaged $319764.7 across 5 years, with a median of $270000.0 in 2022.
- Annual changes were most pronounced in 2021 — Accumulated Depreciation plunged 70.42% — and 2022, when it soared 35.12%.
- Rein Therapeutics' Accumulated Depreciation stood at $522000.0 in 2019, then tumbled by 68.2% to $166000.0 in 2020, then grew by 27.71% to $212000.0 in 2021, then gained by 27.36% to $270000.0 in 2022, then jumped by 32.59% to $358000.0 in 2023.
- Business Quant data shows RNTX's Accumulated Depreciation at $358000.0 in Q4 2023, $295000.0 in Q3 2023, and $285000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 358,000.00 |
| Sep 30, 2023 | 295,000.00 |
| Jun 30, 2023 | 285,000.00 |
| Mar 31, 2023 | 272,000.00 |
| Dec 31, 2022 | 270,000.00 |
| Sep 30, 2022 | 256,000.00 |
| Jun 30, 2022 | 240,000.00 |
| Mar 31, 2022 | 227,000.00 |
| Dec 31, 2021 | 212,000.00 |
| Sep 30, 2021 | 196,000.00 |
| Jun 30, 2021 | 181,000.00 |
| Mar 31, 2021 | 168,000.00 |
| Dec 31, 2020 | 166,000.00 |
| Sep 30, 2020 | 629,000.00 |
| Jun 30, 2020 | 612,000.00 |
| Mar 31, 2020 | 547,000.00 |
| Dec 31, 2019 | 522,000.00 |
| Dec 31, 2018 | 1.21 Mn |
| Dec 31, 2017 | 1.98 Mn |
| Dec 31, 2016 | 2.09 Mn |